Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $41.20 in the prior trading day, GSK Plc ADR (NYSE: GSK) closed at $40.86, down -0.83%. In other words, the price has decreased by -$0.83 from its previous closing price. On the day, 3.92 million shares were traded. GSK stock price reached its highest trading level at $41.295 during the session, while it also had its lowest trading level at $40.83.
Ratios:
Our goal is to gain a better understanding of GSK by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 14.31 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 13.07. For the most recent quarter (mrq), Quick Ratio is recorded 0.58 and its Current Ratio is at 0.87. In the meantime, Its Debt-to-Equity ratio is 1.30 whereas as Long-Term Debt/Eq ratio is at 1.16.
On April 15, 2025, Exane BNP Paribas started tracking the stock assigning a Neutral rating and target price of $35.25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Sep 27 ’24 when GSK plc bought 2,791,930 shares for $8.00 per share. The transaction valued at 22,335,440 led to the insider holds 16,775,691 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GSK now has a Market Capitalization of 83044679680 and an Enterprise Value of 180329086976. As of this moment, GSK’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.21, and their Forward P/E ratio for the next fiscal year is 8.30. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.06 while its Price-to-Book (P/B) ratio in mrq is 4.57. Its current Enterprise Value per Revenue stands at 5.719 whereas that against EBITDA is 20.838.
Stock Price History:
The Beta on a monthly basis for GSK is 0.52, which has changed by -0.0048708916 over the last 52 weeks, in comparison to a change of 0.11730647 over the same period for the S&P500. Over the past 52 weeks, GSK has reached a high of $44.67, while it has fallen to a 52-week low of $31.72. The 50-Day Moving Average of the stock is 7.94%, while the 200-Day Moving Average is calculated to be 8.84%.
Shares Statistics:
The stock has traded on average 5.43M shares per day over the past 3-months and 4423650 shares per day over the last 10 days, according to various share statistics. A total of 2.04B shares are outstanding, with a floating share count of 2.03B. Insiders hold about 0.00% of the company’s shares, while institutions hold 18.11% stake in the company. Shares short for GSK as of 1747267200 were 16757180 with a Short Ratio of 3.08, compared to 1744675200 on 16389128. Therefore, it implies a Short% of Shares Outstanding of 16757180 and a Short% of Float of 0.83.
Dividends & Splits
In the trailing 12 months, GSK’s forward annual dividend rate was 0.62, compared to 1.61 this year. Against a Trailing Annual Dividend Yield of 0.015054024The stock’s 5-year Average Dividend Yield is 4.77. The current Payout Ratio is 94.89% for GSK, which recently paid a dividend on 2025-05-16 with an ex-dividend date of 1747353600. Stock splits for the company last occurred on 2022-07-22 when the company split stock in a 1226:1000 ratio.
Earnings Estimates
The market rating of GSK Plc ADR (GSK) is currently shaped by the ongoing analysis conducted by 2.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $1.34, with high estimates of $1.39 and low estimates of $1.28.
Analysts are recommending an EPS of between $4.44 and $4.16 for the fiscal current year, implying an average EPS of $4.3. EPS for the following year is $4.82, with 4.0 analysts recommending between $5.0 and $4.48.
Revenue Estimates
6 analysts predict $7.92B in revenue for the current quarter. It ranges from a high estimate of $8.29B to a low estimate of $7.72B. As of the current estimate, GSK Plc ADR’s year-ago sales were $7.88BFor the next quarter, 6 analysts are estimating revenue of $8.23B. There is a high estimate of $8.37B for the next quarter, whereas the lowest estimate is $8.02B.
A total of 18 analysts have provided revenue estimates for GSK’s current fiscal year. The highest revenue estimate was $32.98B, while the lowest revenue estimate was $31.5B, resulting in an average revenue estimate of $32.23B. In the same quarter a year ago, actual revenue was $31.38BBased on 19 analysts’ estimates, the company’s revenue will be $34.05B in the next fiscal year. The high estimate is $35.86B and the low estimate is $32.84B.
